Menu
FDA DECISION ·
Keytruda / Keytruda Qlex
pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph · Merck
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults and children with unresectable or metastatic solid tumors with a tumor mutational burden (TMB) of at least 13 mutations per megabase by an FDA-authorized test, after prior treatment and without satisfactory alternatives.
SUPPORTING DATA
Evidence behind the decision
- Study
- FDA evaluated 220 participants with TMB of at least 13 mutations/Mb across KEYNOTE-158 cohorts.
- Key result
- The combined objective response rate was 36% (95% CI, 30%–43%). FDA raised the threshold from 10 to 13 mutations/Mb in the updated indication.
- Safety to report
- FDA described the safety profile as consistent with known pembrolizumab monotherapy safety.
- Evidence limits
- The FDA review did not confirm efficacy sufficient for traditional approval at TMB values from 10 to below 13.
LAMPGEN ANALYSIS
Why it matters
The conversion raised the cutoff from 10 to 13 mutations per megabase. Patients previously eligible at 10 to below 13 fall outside this updated indication because FDA did not confirm benefit at those values.
What research teams should watch
Review assay reports for the numeric TMB value and test authorization before applying the revised threshold. Track how protocol or treatment-pathway documents handle patients near the cutoff.
PRIMARY RECORDS